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Puumala hantavirus is present in bank voles (Myodes 
glareolus) and is believed to be spread mainly by contami-
nated excretions. In this study, we subcutaneously inocu-
lated 10 bank voles with Puumala virus and sampled excre-
tions until day 133 postinfection. Levels of shed viral RNA 
peaked within 11–28, 14–21, and 11–28 days postinfection 
for saliva, urine, and feces, respectively. The latest detec-
tion of viral RNA was 84, 44, and 44 days postinfection in 
saliva, urine, and feces, respectively. In contrast, blood of 
5 of 6 animals contained viral RNA at day 133 postinfec-
tion, suggesting that bank voles secrete virus only during 
a limited time of the infection. Intranasal inoculations with 
bank vole saliva, urine, or feces were all infectious for virus-
negative bank voles, indicating that these 3 transmission 
routes may occur in nature and that rodent saliva might play 
a role in transmission to humans.
H
antavirus, a genus within the family Bunyaviridae, 
contains rodent-borne viruses that cause 2 severe dis-
eases in humans: hantavirus cardiopulmonary syndrome in 
the Americas and hemorrhagic fever with renal syndrome 
(HFRS) in Eurasia. HFRS causes ≈150,000–200,000 hos-
pitalizations each year throughout the world (1). Puumala 
virus (PUUV), which is spread in large areas of Europe, 
causes a milder form of HFRS called nephropathia epi-
demica (2). Since 1989, when the disease became notiﬁ  -
able in Sweden, the largest number of cases was reported 
during 2007 (2,195) compared with a median 207.5 cases 
during 1990–2007 (M. Hjertqvist, pers. comm.). The mean 
incidence of nephropathia epidemica in the 4 northernmost 
county councils in Sweden was as high as 225.5/100,000 
in 2007 (3).
PUUV is carried and maintained by infected bank 
voles (Myodes glareolus); transmission is believed to oc-
cur by inhalation of virus-containing, aerosolized, rodent 
excreta (4). Infectious PUUV has been detected in saliva, 
urine, and feces from experimentally infected colonized 
bank voles (5), and excreted PUUV is infectious for up 
to 12–15 days outside the host (6). However, the relative 
importance of saliva, urine, and feces in transmission of 
PUUV between bank voles or from bank voles to humans 
and how levels of virus change over time in different excre-
tions are not known.
In this study, we used real-time reverse transcription–
PCR (RT-PCR) to measure levels of shed viral RNA in 
saliva, urine, and feces of subcutaneously inoculated bank 
voles until they were killed at day 133 postinfection (PI). 
To evaluate possible transmission routes for PUUV, we 
investigated infectivity of different excretions and used a 
subset of viral RNA–positive saliva, urine, and feces sam-
ples to intranasally inoculate virus-negative bank voles.
Materials and Methods
Animals and Virus
Colonized bank voles were maintained in separate 
cages in biologic safety isolators with food and water pro-
vided ad libitum. All handling of animals was in compli-
ance with guidelines of the Swedish Institute for Infectious 
Disease Control, Stockholm, Sweden. The PUUV strain 
Kazan wild type (PUUV Kazan-wt) (7,8) was used for 
subcutaneous inoculation of bank voles, and Vero E6 cell 
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line–adapted PUUV strain Kazan (PUUV Kazan-E6) (7) 
was used in inhibition experiments and as a positive control 
in the real-time RT-PCR.
Subcutaneous Inoculation and Sample Handling
Bank voles were subcutaneously inoculated with ≈200 
bank vole 50% infectious doses of PUUV Kazan-wt diluted 
in Hanks balanced salt solution medium (Invitrogen, Pais-
ley, Scotland). Animals were sampled for saliva, urine, and 
feces on days 0, 1, 2, 3, 4, 8, 9, 11, 14, 16, 21, 28, 35, 42, 
49, 56, 63, 70, 77, 84, 91, and 133 PI. Serum samples were 
obtained on day 21 and at the termination of the experiment 
(day 133 PI). Some animals did not survive until day 133, 
but they were sampled by using the same procedures until 
time of death.
Saliva was collected by gently rotating a moistened 
cotton swab in the mouth of the bank vole. The cotton swab 
was subsequently placed in a cryotube containing 500 μL 
dilution medium (Hanks balanced salt solution medium 
containing 2% HEPES [Invitrogen], 2% fetal calf serum 
[Sigma-Aldrich, St. Louis, MO, USA], and 1% penicillin-
streptomycin [Sigma]). Urine was collected by grasping 
the scruff of the neck of the animal and holding it over a 
petri dish to cause urination, as described by Botten et al. 
(9). Urine samples were stored in cryotubes. For feces sam-
pling, bank voles were placed in separate containers until 
feces could be collected and transferred into cryotubes. All 
saliva, urine, and feces samples were stored at –70°C until 
analyzed. Serum samples were stored at –20°C until ana-
lyzed for antibodies to PUUV by ELISA.
Intranasal Inoculation
Intranasal inoculation was performed by using subsets 
of the PUUV RNA–positive excretion samples from sub-
cutaneously inoculated bank voles (pooled saliva samples 
from bank voles no. 6 [day 21] and no. 7 [day 21]; pooled 
urine samples from bank voles no. 10 [day 16], no. 1 [day 
21], no. 8 [day 28], and no. 7 [day 14]; and feces suspen-
sion from bank vole no. 3 [day 21]). A total of 5 μL of 
saliva, urine, or feces suspension was delivered to each 
nostril of 14 anesthetized bank voles. Saliva, urine, and fe-
ces were administered to groups of 4, 5, and 5 bank voles, 
respectively. These intranasally inoculated bank voles were 
sampled for saliva, urine, and feces on days 0, 6, 14, 21, 26, 
35, and 42 PI, and a subset of these samples was tested for 
PUUV RNA by real-time RT-PCR. Animals were bled at 
days 21 and 42 PI and then humanely killed. All handling 
of samples was performed as described for the subcutane-
ous inoculation experiment.
ELISA
To conﬁ  rm PUUV infection of the animals, a PUUV-
nucleocapsid immunoglobulin (Ig) G ELISA (10) was per-
formed by using serum from day 21 PI for the subcutane-
ous inoculation experiment, and from days 21 and 42 PI 
for the intranasal inoculation experiment. Brieﬂ  y, 1 μg/mL 
of rKAZ (Escherichia coli–expressed recombinant PUUV 
Kazan) was coated on a 96-well plate. After washing and 
blocking, samples to be tested were added to the plate in 
duplicate at dilution of 1:200. After washing, alkaline phos-
phatase–conjugated goat anti-mouse IgG (Jackson Immuno 
Research, West Grove, PA, USA) was added to the plate. 
The plate was washed again and p-nitrophenyl phosphate 
(Sigma-Aldrich) substrate was added; the optical density 
was determined at 405–620 nm.
Extraction of RNA
Viral RNA was extracted by using the Ex-tract DNA/
RNA Extraction Kit (Severn Biotech Ltd., Kidderminster, 
UK) with procedures described by Boom et al. (11) with 
minor modiﬁ  cations. For saliva samples, 100 μL of sample 
was transferred into a new tube containing 100 μL of dilu-
tion medium, 20 μL of silica particles, and 1 mL of L6 
buffer. Urine samples were centrifuged at 1,800 × g for 5 
min, and 20 μL of supernatants was transferred to a new 
tube containing 180 μL of dilution medium, 20 μL of silica 
particles, and 1 mL of L6 buffer. Approximately 50 mg of 
fecal sample was homogenized in 600 μL of phosphate-
buffered saline (PBS) and centrifuged at 1,800 × g for 5 
min. A total of 200 μL of supernatant was transferred to 
a tube containing 20 μL of silica particles and 1 mL of L6 
buffer.
Tubes were vortexed for 10 s and incubated for 15 min 
at room temperature on a shaker. After centrifugation at 
15,700 × g for 45 s, pellets were washed twice with 1 mL of 
L2 buffer, twice with 1 mL of 70% ethanol, and once with 
1 mL of acetone. After acetone removal, the pellet was 
dried at 56°C for 5–10 min, dissolved in 49 μL of RNase-
free water (Invitrogen) and 1 μL of RNaseOUT (Invitro-
gen), and incubated at 56°C for 15 min. After centrifuga-
tion at 15,700 × g for 4 min, the supernatant was transferred 
into a new tube and immediately analyzed for viral RNA by 
using real-time RT-PCR. PUUV Kazan-E6 (30,000 focus-
forming units [FFU]/mL) was used as a positive control.
Real-Time RT-PCR
A real-time RT-PCR targeting the small seg-
ment of the PUUV genome was performed by using the 
QuantiTect Probe RT-PCR Kit (QIAGEN, Hilden Ger-
many). The reaction consisted of 1× QuantiTect Probe 
RT-PCR master mixture, 300 nmol/L forward primer 
983F (5′-GTGCACCAGATCGGTGTCC-3′) (Invit-
rogen) (12), 900 nmol/L reverse primer 1038R (5′-
CAATTCAGCCATCCCAGCA-3′) (Invitrogen) (12), 
150 nmol/L TaqMan MGB probe 1003T (5′-
CCTACATGCATTTATG-3′) (Applied Biosystems, War-
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rington, UK) (12), 0.25 μL of QuantiTect RT mixture, 5 μL 
of sample RNA (corresponding to RNA from 2 μL urine, 
≈5 mg feces, or 10 μL oral swab suspension), and RNase-
free water (Invitrogen) to give a ﬁ  nal volume of 25 μL. A 
96-well plate (Bio-Rad Laboratories, Hercules, CA, USA) 
was used, and PCR thermal cycling was performed by us-
ing an iCycler (Bio-Rad Laboratories) with the following 
cycling conditions: 50°C for 30 min and 95°C for 15 min, 
followed by 45 cycles at 94°C for 15 s and 60°C for 1 min. 
All samples were tested in duplicate.
Evaluation of Real-Time RT-PCR Inhibition 
by Bank Vole Excretions
Samples of saliva, urine, and feces from uninfected 
bank voles were prepared similarly to samples from infect-
ed bank voles. Saliva was diluted twice in dilution medium, 
urine was diluted 10 times in dilution medium, and feces 
was prepared as an 8% suspension in PBS. Uninfected 
samples were spiked with PUUV Kazan-E6 at 10-fold se-
rial dilutions ranging from 30 to 30,000 FFU/mL. Dilution 
medium and PBS were used as controls. All samples were 
extracted and analyzed in duplicate by using real-time RT-
PCR.
Results
Inhibition of PUUV Real-Time RT-PCR by Feces
Urine and saliva samples showed cycle threshold val-
ues similar to dilution medium and the PBS control for all 
viral dilutions. However, feces samples spiked with PUUV 
Kazan-E6 showed cycle threshold values ≈3–6 cycles 
above control values (Figure 1), which has been shown to 
correspond to 10–100× lower detection of RNA for all viral 
dilutions (13).
Kinetics of Excreted PUUV RNA from Subcutaneously 
Inoculated Bank Voles
Ten colonized male bank voles were subcutaneously 
inoculated with PUUV Kazan-wt. All bank voles serocon-
verted, as shown by an IgG ELISA that used serum sam-
ples obtained from animals at day 21 PI. Four bank voles 
did not survive until day 133; bank voles no. 4 and 9 died 
after being anesthetized on day 21 PI, and bank voles no. 
5 and 10 died of unknown reasons on 112 and 35 days PI, 
respectively.
Viral RNA was detected in subsets of saliva, urine, 
and feces samples (Figure 2, Table 1). Cycle threshold val-
ues of negative samples were set at 45. Levels of excreted 
PUUV RNA peaked on days 11–28 PI for saliva, 14–28 
PI for urine, and 11–28 PI for feces. The earliest and latest 
detection of PUUV RNA was found for saliva on days 8 
and 84 PI, compared with 11 and 44 days PI for urine and 
feces. One animal (no. 2) was PUUV RNA negative in all 
urine samples, and 1 animal (no. 10, which died on day 35 
PI) was negative in all feces samples (Table 1). Viral RNA 
was detected in serum from 5 of the 6 surviving animals at 
day 133.
Intranasal Transmission of PUUV by Bank Vole 
Saliva, Urine, and Feces
We tested whether RNA-positive excretion samples 
also contained infectious virus and whether intranasal in-
oculation was a possible route of infection for all types of 
excretions. A subset of the PUUV RNA–positive urine, 
feces, and saliva samples collected from subcutaneously 
inoculated bank voles was administered intranasally to 14 
virus-negative female bank voles. Seven (2/4 given saliva, 
2/5 given urine, and 3/5 given feces) of 14 intranasally in-
oculated bank voles seroconverted (Table 2).
Saliva, urine, and feces samples were obtained from 
the 14 intranasally inoculated animals and tested by real-
time RT-PCR. PUUV RNA was detected in subsets of sa-
liva, urine, and feces samples from all 3 groups (Table 2).
Discussion
We have shown in controlled experimental conditions 
how levels of shed PUUV RNA change over time in sa-
liva, urine, and feces from PUUV-infected bank voles. All 
3 excretions can transmit virus to other bank voles when 
administered intranasally, which suggests that all 3 excre-
tion pathways can function as natural transmission routes 
between bank voles and from bank voles to humans.
In previous studies on PUUV, experimentally infected 
bank voles seem to excrete infectious virus for a limited 
time after infection (5,14). This ﬁ  nding is consistent with 
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Figure 1. Inhibition of Puumala virus (PUUV) real-time reverse 
transcription–PCR by feces, but not saliva or urine, of bank voles. 
Mean cycle threshold values are shown for different solutions 
spiked with a cell line–adapted PUUV. Cycle threshold values of 
negative samples were set at 45. PBS, phosphate-buffered saline; 
FFU, focus-forming units.RESEARCH
our real-time RT-PCR data. We observed clear peaks of 
shed viral RNA in saliva, urine, and feces preceded and 
followed by levels below detection limits. Viral RNA was 
detected in blood of 5 of 6 surviving animals on day 133, 
which suggested that persistently infected bank voles do 
not normally shed virus during the entire course of infec-
tion. Levels of excreted viral RNA decreased below the 
detection level in some animals, but RNA was detected in 
subsequent samples (Figure 2).
Similar patterns have been observed for Sin Nombre 
virus (SNV)–infected deer mice (Peromyscus manicula-
tus). Botten et al. reported an initial peak in SNV RNA 
levels in lung samples at 21 days PI, followed by a sec-
ond peak at 60 days PI (15). In another report on SNV, 
Kuenzi et al. found a variation in PCR positivity of blood 
samples from wild-caught deer mice (16). These authors 
suggested 2 interpretations of the results: either that viral 
RNA is consistently present in the blood but is near the lim-
its of PCR detectability or viral RNA reappears in blood as 
a consequence of unknown physiologic events. We believe 
that similar interpretations can be made concerning levels 
of PUUV RNA in bank vole excretions. Whether levels of 
excreted PUUV change as a consequence of external fac-
tors, e.g., cold temperatures or social stress, remain to be 
shown.
A problem when working with biologic material com-
bined with PCR techniques is the effect of inhibitory sub-
stances; several inhibitory components in feces have been 
identiﬁ  ed, such as bile salts and polysaccharides (17). In the 
spiking experiments, saliva and urine showed no PCR in-
hibition because results for excretions were comparable to 
those of dilution medium and PBS (similar cycle threshold 
values). In contrast, 10–100× less viral RNA was recov-
ered from spiked feces samples (Figure 1), which indicated 
that more virus was shed in bank vole feces than we were 
able to detect. We conclude that saliva contained higher 
levels of viral RNA than urine did because saliva samples 
were ≈10–20× more diluted than the urine samples but still 
showed lower cycle threshold values.
Although real-time RT-PCR is an effective method 
for measuring levels of RNA, it does not necessarily mea-
sure the presence of infectious virions. We therefore tested 
a subset of real-time RT-PCR–positive excretion samples 
for infectious virus. Different methods can be used to de-
tect infectious hantavirus and potential transmission routes. 
Bernshtein et al showed that more bank voles were infected 
when injected with lung suspension from PUUV-positive 
bank voles than after intercage transmission (14). Injection 
shows if an excretion contains infectious virus, but in na-
ture a similar event will occur only when saliva is trans-
ferred by biting. Especially for urine and feces, intranasal 
inoculation probably resembles natural transmission. Bank 
vole saliva, urine, and feces are infectious when injected in-
tramuscularly into virus-negative bank voles (5). We show 
that saliva, urine, and feces are also infectious when given 
intranasally, which indicates that PUUV in bank vole saliva 
can be transferred not only by biting. Intranasal inhalation 
of saliva may also involve ingestion, which may also be a 
viable route of infection. Ingestion could occur when sev-
eral bank voles share a common food source. Hooper et al. 
have recently shown that Andes hantavirus is infectious to 
hamsters when administered by intragastric injection and 
speculate that ingestion of contaminated material might be 
a mode of transmission to humans (18).
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Figure 2. Detection of Puumala virus (PUUV) RNA by real-time 
reverse transcription–PCR in saliva, urine, and feces of bank voles 
subcutaneously inoculated with PUUV strain Kazan wild type. Cycle 
threshold values of negative samples were set at 45. *, bank voles 
4 and 9 died on day 21 postinfection and bank voles 5 and 10 died 
on days 112 and 35 postinfection, respectively.Puumala Hantavirus Excretion Kinetics, Bank Voles
We have shown that intranasal inoculation of saliva, 
urine, or feces enables subsequent detection of viral RNA 
in all types of excretions, which indicates that virions ex-
creted by different routes do not show restricted tropism for 
particular tissues. When we analyzed serum obtained on day 
42 PI from intranasally inoculated bank voles by ELISA, 7 
of 14 had seroconverted (Table 2). Only 1 of the animals 
was positive at day 21 PI (Table 2). This late seroconver-
sion in bank voles may have been caused by relatively low 
doses of virus in bank vole saliva, urine, and feces samples 
used for intranasal inoculation. We believe that this infor-
mation will be useful in future vaccine and infection studies 
because it indicates that a low level of hantavirus might 
not induce seroconversion until after 21 day PI. It would 
be useful to investigate whether a low dose of hantavirus 
inoculum can induce seroconversion after 42 day PI.
To better evaluate and predict risk for human hantavi-
rus infections, information on factors associated with oc-
currence and transmission of hantavirus in natural rodent 
populations is needed. It has been assumed that rodent be-
havior is required for maintenance of PUUV in the natural 
reservoir because PUUV infection in relation to bank vole 
demography shows nonrandom transmission patterns (19). 
PUUV stability outside the host likely plays a role in trans-
mission to other rodents and in the number of human cases 
(20). Hantaviruses have been shown to be stable ex vivo, 
and Hantaan hantavirus can infect cell culture after being 
stored for as long as 96 days in medium at 4°C (21). Fur-
thermore, PUUV is infectious for bank voles for up to 12–
15 days in contaminated cage bedding (6). How different 
excretions contribute to virus stability in the environment 
and what implications this might have on direct versus in-
direct transmission among rodent reservoirs remain to be 
shown. The role of different excretions in transmission of 
PUUV may vary with the age and density of bank voles 
and the season. Hypothetically, shedding in saliva might 
be more efﬁ  cient for virus transmission in male bank voles 
living in a high-density area during mating season, when 
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Table 1. Detection of PUUV RNA over time in excreta from bank voles subcutaneously inoculated with PUUV strain Kazan wild type*
Detection of PUUV RNA in excreta by time, d Bank
vole
no.
Excretion
type  1 2 3 4 8 9 11 14 16 21 28 35 44 49 56 63 70 77 84 91 133
Saliva – – – – + – – – – + + – – – – – – – – – –
Urine NT – NT NT NT NT – – – NT + – NT NT – NT NT – NT NT –
1
F e c e s ––––––+––––+–––––––––
Saliva – – – – – + + + + + + – – + – – – + – – –
Urine – NT – NT NT NT – NT NT – – – NT NT NT NT – NT – NT NT
2
F e c e s –––––––––++–+––––––––
Saliva – – – – – + + + + + + + + + + + – – + – –
Urine – – NT NT – NT + NT + NT – – + NT NT NT – NT NT NT NT
3
F e c e s ––––––––+++––––––––––
Saliva – – – – – – – + + +
Urine – – NT NT NT NT – – – +
4†
F e c e s –––––––+++
Saliva – – – – – – + + + + + + + – + – – – – –
Urine NT – NT – NT NT + + NT NT NT NT NT – – NT – NT NT NT
5‡
F e c e s ––––––––+–+–––––––––
Saliva – – – – – – + + + + + + + + + – – - + – –
Urine – NT – NT NT – NT NT + NT NT + – NT – NT – NT - – NT
6
F e c e s ––––––––++––+––––––––
Saliva – – – – – – + + + + + + + + – – – – – – –
Urine – NT NT NT NT – – + + + – NT – NT – NT – NT – NT NT
7
F e c e s –––––––+++–-–––––––––
Saliva – – – – – – + + + + + + + + – – – – – – –
Urine – – – NT NT – – – + – NT – – – – – NT – – NT –
8
F e c e s –––––––+–––––––––––– -–
Saliva – – – – – – – – + +
Urine NT NT – – – – – NT + +
9†
F e c e s ––––––––– -+
Saliva – – – – – + + + + + + +
Urine NT NT – NT NT NT NT – + + – +
10§
F e c e s ––––––––––––
*PUUV, Puumala virus; –, negative; +, positive, NT, not tested (no or insufficient urine volume). 
†Died on day 21 postinfection. 
‡Died on day 112 postinfection. 
§Died on day 35 postinfection. RESEARCH
many ﬁ  ghts occur. In contrast, shedding in feces, which 
may provide the virus with a more stable environment, may 
play a more dominant role in transmission in a low-density 
area during fall or winter.
In conclusion, we studied levels of PUUV RNA in 
excretions of infected bank voles over a period of 4.5 
months. We have shown that bank vole saliva, urine, and 
feces can cause infection when inhaled by other bank 
voles, which indicates that all 3 excretions can transfer 
virus to humans.
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